Innate Pharma Partners with Sobi for Lacutamab Phase 3 Development and Appoints New CMO
On August 10, 2026, Innate Pharma announced a strategic partnership with Swedish Orphan Biovitrum AB (Sobi) to license lacutamab, a first-in-class anti-KIR3DL2 antibody for T-cell lymphoma. Under the agreement, Sobi will pay Innate an upfront payment of $75 million, with eligibility for an additional $40 million in near-term development milestones for SΓ©zary syndrome. Innate could receive up to $465 million in further regulatory and commercial milestones, plus tiered double-digit royalties. The partnership enables the initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), supporting a planned accelerated approval filing in SΓ©zary syndrome. Sobi gains exclusive global commercialization rights and an option for full global development rights. The $75 million payment extends Innate's cash runway through Q3 2027. Additionally, Innate announced the appointment of Markus Jensen as Chief Medical Officer, effective September 1, 2026, succeeding Sonia Quaratino to oversee this late-stage clinical execution.